Literature DB >> 7620166

Molecular analysis of clonality in Castleman's disease.

J Soulier1, L Grollet, E Oksenhendler, J M Micléa, P Cacoub, A Baruchel, P Brice, J P Clauvel, M F d'Agay, M Raphael.   

Abstract

Castleman's disease (CD) is a rare atypical lymphoproliferative disorder that is morphologically and clinically heterogenous and is associated with a risk of developing malignant lymphoma. We report the clonality status of CD tissues in 34 patients, including 14 patients infected by the human immunodeficiency virus (HIV). Four patients presented a localized form and 30 presented a multicentric form. Two cases were associated with B-cell lymphoma, 3 cases with Hodgkin's disease, and 9 cases (8 HIV+) with Kaposi's sarcoma. Histologically, 8 cases were of the hyaline-vascular type and 26 were of the plasma cell or mixed types. The Ig and T-cell receptor (TCR) V(D)J rearrangements were analyzed using polymerase chain reaction and Southern blot. Clonal IgH rearrangements were detected in only 4 cases, ie, 2 associated with B-cell lymphoma, 1 with Hodgkin's disease, and 1 case without malignancy. A TCR gamma rearrangement of restricted junctional size was amplified in 1 HIV+ case. Finally, polyclonal VH-JH and V gamma-J gamma rearrangements were detected in the large majority of the cases, irrespective of pathologic subtypes, clinical forms, and HIV status. The lymphoid component in CD is therefore commonly reactive, and the rare occurrence of detectable monoclonal lymphoid contingents may be caused by secondary molecular events.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620166

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately.

Authors:  Xuan Lan; Zhaoming Li; Mingzhi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-07       Impact factor: 4.553

2.  Blockade of viral interleukin-6 expression of Kaposi's sarcoma-associated herpesvirus.

Authors:  Yan-Jin Zhang; Rheba S Bonaparte; Deendayal Patel; David A Stein; Patrick L Iversen
Journal:  Mol Cancer Ther       Date:  2008-03       Impact factor: 6.261

Review 3.  Castleman's disease in childhood: report of three cases and review of the literature.

Authors:  Piero Farruggia; Antonino Trizzino; Nunzia Scibetta; Giovanni Cecchetto; Patrizia Guerrieri; Emanuele S G D'Amore; Paolo D'Angelo
Journal:  Ital J Pediatr       Date:  2011-10-20       Impact factor: 2.638

4.  Murine gammaherpesvirus 68 LANA is essential for virus reactivation from splenocytes but not long-term carriage of viral genome.

Authors:  Clinton R Paden; J Craig Forrest; Nathaniel J Moorman; Samuel H Speck
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

5.  Multicentric Castleman's Disease.

Authors:  M K Gupta; S K Magu; A Behl
Journal:  Med J Armed Forces India       Date:  2011-07-21

6.  Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 transcriptional activator Rta is an oligomeric DNA-binding protein that interacts with tandem arrays of phased A/T-trinucleotide motifs.

Authors:  Wei Liao; Yong Tang; Yu-Liang Kuo; Bao-Ying Liu; Chi-Jie Xu; Chou-Zen Giam
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 7.  [Lymphadenopathy: demarcation to malignant lymphomas].

Authors:  A C Feller
Journal:  Pathologe       Date:  2013-05       Impact factor: 1.011

8.  Feline Herpesvirus 1 US3 Blocks the Type I Interferon Signal Pathway by Targeting Interferon Regulatory Factor 3 Dimerization in a Kinase-Independent Manner.

Authors:  Jin Tian; Yongxiang Liu; Xiaoxiao Liu; Xue Sun; Jikai Zhang; Liandong Qu
Journal:  J Virol       Date:  2018-05-29       Impact factor: 5.103

Review 9.  CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases.

Authors:  Jing Li; Shu Zhao; Jingxuan Wang; Jingyu Chen; Wen Wen; Qingyuan Zhang
Journal:  Tumour Biol       Date:  2015-10-12

10.  Establishment of a primary effusion lymphoma cell line (RM-P1) and in vivo growth system using SCID mice.

Authors:  Jun-ichi Miyagi; Masato Masuda; Nobuyuki Takasu; Akitoshi Nagasaki; Tetsuharu Shinjyo; Hiroshi Uezato; Naoki Kakazu; Yuetsu Tanaka
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.